Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05765266 · ClinicalTrials.gov registry record · NA
ACP Max™ PRP System for Knee Osteoarthritis: A Feasibility Trial
A NA study, sponsored by Arthrex.
- Completed
- Registry status
- NA
- Development phase
- 45
- Enrollment target
NCT05765266 is a NA study that has completed, run by Arthrex. The registered enrollment target is 45 participants.
The verdict
NCT05765266, a NA study, has completed, sponsored by Arthrex.
- COMPLETED
- Registry status
- NA
- Development phase
- 45 participants
- Enrollment target
Study Summary
This study is a prospective, multicenter (up to 4 sites), randomized, double-blind, two-arm study. Forty-five (45) patients will be randomized to receive a single 4-6 ml intra-articular (IA) injection of either the output of ACP Max™ (n=30) or 6 ml of Depo-Medrol® (methylprednisolone acetate) (n=15).
Interventions
- DEVICE ACP Max™
- DEVICE Depo-Medrol®
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2024-05-13 |
| Est. Completion | 2026-02-09 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05765266
The ClinicalTrials.gov registry entry for NCT05765266 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Arthrex, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which ACP Max™ is the first listed.
NCT05765266 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05765266 about?
NCT05765266 is a clinical study titled "ACP Max™ PRP System for Knee Osteoarthritis: A Feasibility Trial". This study is a prospective, multicenter (up to 4 sites), randomized, double-blind, two-arm study. Forty-five (45) patients will be randomized to receive a single 4-6 ml intra-articular (IA) injection of either the output of ACP Max™ (n=30) or 6 ml of Depo-Medrol® (methylprednisolone acetate) (n=15)...
What is the current status of trial NCT05765266?
This trial is currently completed. It is a NA study. The enrollment target is 45 participants. The study started on 2024-05-13. Estimated completion is 2026-02-09.
What interventions are being tested in trial NCT05765266?
The interventions under investigation include: ACP Max™ (DEVICE), Depo-Medrol® (DEVICE).
Who is sponsoring clinical trial NCT05765266?
This trial is sponsored by Arthrex, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.